InMed Pharmaceuticals (NASDAQ: INM) "Addressing The Increasing Demand For Rare Cannabinoids" 1-6-22

We are excited to be hosting Tribe Public's Next Webinar Presentation and Q&A Event which will be held Thursday, January 6, 2022 (8 am PT/ 11 am ET). Our events are approximately 30 minutes in duration.

Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) SVP, General Manager of BayMedica Shane Johnson, MD & VP, Commercial Operations Chris Meiering, PhD will co-host a presentation and Q&A event titled "Addressing The Increasing Demand For Rare Cannabinoids". They will be available for a 5-10 minute Q&A session at the end of the presentation, so please send your questions for management to Tribe's email: [email protected].

InMed Pharmaceuticals (NASDAQ: INM) is a global leader in the development, manufacturing, and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.

Please consider doing the to join Tribe Public (www.tribepublic.com) for our future complimentary events & to receive future FREE invitations. Disclaimer: https://tribepublic.com/disclaimers.
Be the first to comment